Premium
D‐dimer and CA 125 levels in patients with ovarian cancer during antineoplastic therapy prognostic significance for the success of anti‐cancer treatment
Author(s) -
Mirshahi S. S.,
PujadeLauraine E.,
Soria C.,
Mirshahi M.,
Fretault J.,
Bernadou A.,
Soria J.
Publication year - 1992
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19920501)69:9<2289::aid-cncr2820690914>3.0.co;2-a
Subject(s) - medicine , d dimer , ovarian cancer , chemotherapy , cancer , gastroenterology , fibrin , lung cancer , minimal residual disease , oncology , immunology , leukemia
In patients with ovarian cancer before they receive chemotherapy, the level of fibrin degradation products (D‐dimer), is correlated with the tumor load. In this study, the evolution of D‐dimer was compared in patients receiving antineoplastic therapy with the evolution of the disease. The patients could be classified into three groups. In Group 1 (nine patients), both plasma CA 125 (a tumor‐associated antigen) and D‐dimer remained elevated; the prognosis was always poor. In Group 2 (eight patients), CA 125 and D‐dimer decreased simultaneously, complete remission was observed in two patients, and significant residual tumor was observed in the others. In Group 3 (nine patients), despite an important decrease in CA 125, D‐dimer remained elevated during therapy. In this group, complete remission was observed in six patients, and three others showed a large decrease in their tumor load. The combination of a decrease in CA 125 levels with a continuous enhanced level of D‐dimer during chemotherapy identified a subgroup of patients with a favorable prognosis.